FG001 clinical data in High-Grade Glioma is now published in Neurosurgery
FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to announce its compelling phase I clinical data with FG001 has been published in Neurosurgery. The data is the first-in-human result of its proprietary near-infrared (NIR) optical imaging agent, FG001, in patients with malignant glioma undergoing surgery.
The article, published in the prestigious journal Neurosurgery, which targets neurosurgeons, is entitled "Novel uPAR-targeting optical imaging agent ICG-Glu-Glu-AE105 (FG001) for visualization of malignant glioma during surgery: First-in-human study in 35 brain cancer patients" and identified with doi:10 1227/neu.0000000000003542, available here: link.
"We are very pleased with the publication of the results from this first-in-human study that shows FG001 not only enables safe and targeted tumor identification including in the transition zone, being the tissue between the cancer and normal tissue which constitutesthe biggest challenge for the surgeon treating high-grade glioma - where the agent continued to produce visible fluorescence." said Morten Albrechtsen, CEO of FluoGuide; "FG001 has the potential to redefine how surgeons approach brain tumor resection"
Next clinical step and regulatory pathFollowing the successful completion of this phase I study, FluoGuide is obtaining FDA regulatory advice prior to initiate the U.S. clinical trial supporting approval of FG001 guiding surgery of patients with High Grade Glioma. FluoGuide anticipates feedback from ongoing regulatory interactions over the summer.
"I am pleased to see the first result of FG001 in patients with malignant glioma published" says Jane Skjøth-Rasmussen, MD, PhD, Chief Physician in the Department of Neurosurgery at Rigshospitalet, Copenhagen, Denmark and Principal Investigator of the trial and the author of the publication, and continues: "The data demonstrates FG001 to be well tolerated and shows a promise for guiding surgery of malignant glioma."
In an editorial comment published together with the article Professor Pierre A. Robe, Chair of Neurosurgical Oncology at the University Medical Center (UMC) concludes: "Altogether, the results reported here are a welcome and exciting addition to the brain tumor neurosurgical community." Please refer to the published article for the full commentary.
Glioblastoma is among the most aggressive and lethal forms of brain cancer, with a crucial need for tools that enable maximal tumor resection while preserving healthy brain tissue. FG001 lights up cancer, enabling surgeons to perform more precise surgeries. It is an novel imaging agent that targets the urokinase-type plasminogen activator receptor (uPAR), a protein highly expressed in tumor tissue but largely absent from normal brain cells.
Key results from the phase I studyThe result is from the first clinical trial with FG001 in patients with High Grade Glioma and is an open-label, single-center phase I trial involving 35 patients, and FG001 was administered intravenously prior to brain surgery. A dose of 36 mg administered 12-19 hours before surgery provided optimal tumor visualization. The tumor-to-background fluorescence ratio (TBR) was relevant for all image system tested (>1.5) and up to 2.7 (TBR mean) and 3.6 (TBR max). Notably, FG001 achieved a sensitivity of 79% and a specificity of 100% in identifying malignant tissue confirmed by histopathology.
Compared with the imaging agent 5-ALA, FG001 was observed to provide clearer delineation in deeper tissue layers due to its NIR fluorescence properties, with no observed false positives. FG001's safety profile was equally promising, with only few (4) mild drug-related adverse events linked to the drug. It was observed that unlike 5-ALA, no FG001-related nausea or vomiting was reported in patients receiving evening doses, underscoring FG001s favorable tolerability.
High precision in the transition zoneThe transition zone, being the tissue between the tumor and the normal tissue, is of special attention to neurosurgeons as it is where they must make the difficult decisions between removing tissue that may be cancer and risking disabling patients by removing more brain tissue than necessary. FG001 worked well in the transition zone where all 7 samples were correctly classified by FG001 whereas 5-ALA had 2 false negative. When the efficacy was calculated for transition zone only, then specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) were all 100% for FG001, whereas the numbers were 100%, 60%, 100%, and 50% for 5-ALA, respectively.
For further information, please contact:Morten Albrechtsen, CEOFluoGuide A/SPhone: +45 24 25 62 66E-mail: ma@fluoguide.com
Certified Adviser:Svensk Kapitalmarknadsgransking ABWebsite: www.skmg.se
About FluoGuideFluoGuide is a biotech company specializing in precision cancer surgery improving the outcome for cancer patients. The Company's lead product, FG001, a novel optical imaging agent that light up cancerous tissue to improve surgical precision in patients undergoing surgery. FluoGuide's products are expected to have a dual benefit - reducing both the frequency of local recurrence after surgery and reducing surgical complications. The improved precision will potentially increase the patients' chance of achieving a complete cure and lower healthcare costs. FG001 binds to the urokinase plasminogen activator receptor (uPAR) being extensively expressed by solid cancer. The photosensitizer therapy potential of FG001 could add a direct treatment effect of FG001 to further benefit for patients with cancer undergoing surgery.
The Company has published strong results from phase II trials demonstrating the efficacy of FG001 in patients undergoing surgery to remove aggressive brain (high-grade glioma), head & neck (oral squamous cell carcinoma) and lung cancers (non-small cell lung cancer). FG001 has also been demonstrated very well tolerated across all patients. Based on this strong foundation, FluoGuide advances the development toward approval in aggressive brain cancer and head & neck cancer.
FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker "FLUO". Read more about FluoGuide and upcoming events on www.fluoguide.com
AttachmentsFG001 clinical data in High-Grade Glioma is now published in Neurosurgery
SOURCE: FluoGuide A/S
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
The Stock Warren Buffett Spent $78 Billion Buying Over the Last 7 Years Is Slumping, and It Begs the Question: Has the Oracle of Omaha Lost His Touch?
Key Points Warren Buffett has purchased close to $78 billion worth of his favorite stock since the midpoint of 2018 -- and you won't find it listed in Berkshire Hathaway's quarterly 13F filings. However, Berkshire's billionaire chief hasn't spent a dime buying shares of this stock for at least three quarters -- and there's a good reason why. Buffett sticking to his roots and purposefully sitting on his hands until valuations make sense shouldn't be misconstrued as weakness. 10 stocks we like better than Berkshire Hathaway › Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) billionaire CEO Warren Buffett is widely viewed as Wall Street's greatest money manager. Without relying on fancy charting software or algorithms, the aptly named Oracle of Omaha became one of the richest people in the world and watched Berkshire grow into one of only 11 public companies worldwide to ever hit a $1 trillion valuation. Buffett's track record -- he's overseen a 5,868,186% cumulative return in Berkshire Hathaway's Class A shares (BRK.A) in six decades -- has earned him a huge following, which includes investors who aim to mirror his trading activity. But with Warren Buffett's most-purchased stock over the last seven years recently falling more than 10% as the broad-based S&P 500 and growth-fueled Nasdaq Composite power to fresh all-time highs, the question has to be asked: Has Berkshire's billionaire CEO lost his touch? Warren Buffett's favorite stock is a company near and dear to his heart Most investors track the Oracle of Omaha's buying and selling activity by following Berkshire Hathaway's quarterly Form 13F filings. This required filing for institutional investors with at least $100 million in assets under management concisely lists all buying and selling activity from the previous quarter. However, there's a catch: Buffett's favorite stock to buy isn't listed in his company's quarterly filed 13Fs. To get the skinny on this top stock, you'll need to dig into Berkshire Hathaway's quarterly operating results. On the final page of each quarterly report, just prior to the executive certifications, you'll find a detailed breakdown of exactly how much Wall Street's most-revered billionaire money manager spent on his favorite stock (cue the dramatic music)... which happens to be shares of his own company. Prior to July 2018, Warren Buffett and now-late right-hand man Charlie Munger were only allowed to repurchase shares of Berkshire Hathaway stock if it fell to or below 120% of book value (i.e., no more than 20% above listed book value). Unfortunately, Berkshire's stock never fell to or below this line-in-the-sand threshold, which resulted in no buyback activity. On July 17, 2018, Berkshire's board amended and simplified the rules governing buybacks to two criteria. It allowed the Oracle of Omaha to repurchase shares with no ceiling or end date as long as: Berkshire has at least $30 billion in combined cash, cash equivalents, and U.S. Treasuries on its balance sheet; and Buffett views shares of his company as intrinsically cheap. This latter point is purposefully vague so as to give Buffett the discretion to put his company's capital to work via buybacks whenever he feels it's appropriate. Between July 1, 2018, and March 31, 2025, Berkshire's billionaire chief bought back almost $78 billion worth of his company's shares. This is more than Buffett has spent buying Berkshire's existing stakes in Apple, Bank of America, American Express, Coca-Cola, and Chevron, combined. But the Oracle of Omaha's favorite stock is slumping. As of this writing on July 23, it's down more than 10% from its all-time closing high in early May. Perhaps more importantly, it's underperforming the benchmark S&P 500 on a year-to-date basis. Berkshire Hathaway's slump is a sign of Buffett's resolve and shouldn't be confused with weakness With Berkshire's billionaire chief set to turn 95 in less than five weeks, as well as retiring from the CEO role at the end of this year, few investors would fault him for losing his touch. But what we're witnessing with Berkshire's stock at the moment isn't a sign of Buffett failing. Rather, it's validation of his resolve and investment philosophies. During his six decades as CEO, Buffett has bent a few of his own unwritten investment rules. For instance, while he's often viewed as a long-term investor, he and his top advisors purchased shares of gaming giant Activision Blizzard in 2022 as a short-term arbitrage opportunity given Microsoft's $95-per-share all-cash offer to acquire the company. But the one investment philosophy Warren Buffett hasn't wavered on in six decades is his desire to get a good deal. Value is of the utmost importance to Berkshire Hathaway's billionaire chief. No matter how much he appreciates a company's competitive edge, brand, and/or management team, he's not going to buy shares if the valuation doesn't make sense. When Buffett green-lit the cumulative purchase of nearly $78 billion worth of his favorite stock over 24 quarters (six years), Berkshire Hathaway stock consistently traded at a 30% to 50% premium to its book value. But between July 1, 2024, and March 31, 2025, Buffett hasn't spent a dime to repurchase his company's stock. The reason? Berkshire's premium to book climbed to between 60% and 80%. Even shares of the Oracle of Omaha's own company are off-limits when the valuation no longer makes sense. However, Buffett's cold-turkey approach with his own company's stock isn't unique. He's been a net-seller of equities for 10 consecutive quarters, with $174.4 billion more in stocks sold than purchased. Back in 2001, in an interview with Fortune magazine, Buffett referred to the market-cap-to-GDP ratio as, "probably the best single measure of where valuations stand at any given moment." This valuation tool, which divides the cumulative value of all public companies by U.S. gross domestic product (GDP), has averaged a multiple of 85% when back-tested to 1970. This is to say that the aggregate value of all publicly traded stocks has equaled about 85% of U.S. GDP over 55 years. As of the closing bell on July 22, the "Buffett Indicator," as this valuation measure is now more-commonly known, hit a record high of 212.23%! Value isn't just hard to come by in this market -- it's practically nonexistent. What we're witnessing from Buffett isn't weakness. Rather, we're seeing a time-tested investor sticking to his roots and purposefully sitting on his hands until valuations make sense. Though there's no timeline as to when valuations will fall back into Warren Buffett's (or successor Greg Abel's) wheelhouse, patience has proved to be a virtue and substantial moneymaker in the past for Berkshire's CEO and the company's shareholders. Should you buy stock in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Bank of America is an advertising partner of Motley Fool Money. American Express is an advertising partner of Motley Fool Money. Sean Williams has positions in Bank of America. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, Chevron, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. The Stock Warren Buffett Spent $78 Billion Buying Over the Last 7 Years Is Slumping, and It Begs the Question: Has the Oracle of Omaha Lost His Touch? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Beko Scales Up Climate Action with Green Electricity and Refurbishment
Commitment to be a net zero company by 2050 with ambitious 2030 targets including using 100% green electricity in all manufacturing facilities 114,468 products refurbished in 2024 61.9% of turnover from energy-efficient products; 71.5% from low-carbon products ISTANBUL, July 28, 2025 /PRNewswire/ -- Beko, a leader in home appliances, launched its 2024 Integrated Report, themed around scientist Carl Sagan's profound depiction of Earth as the "pale blue dot." The metaphor underscores our planet's fragility and our collective duty to "preserve and cherish the only home we've ever known." In a world in flux—at a time when sustainability is losing priority in boardrooms—Beko remains steadfast. Its purpose is clear: to inspire sustainable living in every home. This purpose is backed by concrete actions, including a pathway to 100% green electricity by 2030 and a global refurbishment network that extended the life of over 114,000 appliances in 2024. As a recognized sustainability leader, earning the highest score in its industry in the S&P Global Corporate Sustainability Assessment for the sixth consecutive year[i], Beko remains resolved in its commitment to both people and planet. The company was recently ranked 17th among the world's most sustainable companies by TIME Magazine and Statista, topping in its industry and appearing on the list for the second time. These achievements highlight Beko's robust climate strategy, alongside its continued progress in ESG transparency, product efficiency, supply chain responsibility, and social inclusion. The first of its kind from Beko, the integrated report aligns with the International Integrated Reporting Framework (IIRC), Global Reporting Initiative (GRI), Türkiye Sustainability Reporting Standards (TSRS), and Corporate Sustainability Reporting Directive (CSRD). It includes a double materiality assessment, evaluating both how sustainability issues affect Beko's business and how Beko's operations impact society and the environment, combining stakeholders' perspectives with internal analyses to drive tangible actions. This approach reflects the company's long-term strategy—affirming that sustainability is not solely a business priority but a shared global imperative. Hakan Bulgurlu, CEO of Beko, said: "Securing a net-zero future requires absolute focus and concrete action. We are committed to 100% green electricity in manufacturing by 2030 and have dramatically scaled our refurbishment programme. But that's only part of the story. We're continuously working to improve water and waste management, drive down emissions across our supply chain, and design products that do more with less. I'm very grateful for our teams and partners who champion these responsible practices, helping us build a greener, more circular economy. This report showcases how Beko embeds sustainability into every decision, from product design to operations and corporate governance, as we work to protect our 'pale blue dot'." Celebrating 70 years of innovation, Beko continues to lead with purpose and consistency, keeping sustainability at its core: Beko is on a path to Net Zero by 2050, with bold interim targets including using 100% green electricity in all manufacturing facilities by 2030. The company's climate strategy addresses Scope 3 emissions—which account for 99% of its total footprint, with approximately 80% arising during product use phase. Beko has rapidly scaled up its renewable energy investments, reaching a total installed capacity of 90.2 MWp—an almost 30-fold increase in just four years. Beko's circular economy strategy is driving transformation across design, production, and end-of-life product use. Refurbishment is a core enabler of its product lifecycle model. In 2024, the company's global refurbishment network extended the life of 114,468 appliances. These efforts help customers reduce carbon footprints while extending product utility and reducing e-waste. Beko has embedded sustainability into its leadership DNA by linking executive compensation indirectly to environmental performance. Targets for reducing Scope 1, 2, and 3 emissions, along with supply chain sustainability integration, are included in the scorecards of key C-suite leaders. As a member of and signatory to multiple global initiatives, Beko demonstrates its commitment to collaborative climate action. The integrated report is a call to action for stakeholders to unite in preserving Earth's sustainability. For a comprehensive view of Beko's initiatives, visit ABOUT BEKO Beko is an international home appliance company with a strong global presence, operating through subsidiaries in more than 55 countries with a workforce of over 50,000 employees and production facilities spanning multiple regions—including Europe, Asia, Africa, and the Middle East. Beko has 22 brands owned or used with a limited license (Arçelik, Beko, Whirlpool*, Grundig, Hotpoint, Arctic, Ariston*, Leisure, Indesit, Blomberg, Defy, Dawlance, Hitachi*, Voltas Beko, Singer*, ElektraBregenz, Flavel, Bauknecht, Privileg, Altus, Ignis, Polar). Beko became the largest white goods company in Europe with its market share (based on volumes) and reached a consolidated turnover of 10.6 billion Euros in 2024. Beko's 29 R&D and Design Centers & Offices across the globe are home to over 2,300 researchers and hold more than 3,500 international registered patent applications to date. The company has achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) in the DHP Household Durables industry for the sixth consecutive year (based on the results dated 18 February 2025) and has been included in the Dow Jones Sustainability Indices for the eighth consecutive year.** The company has been recognized as the 17th most sustainable company on TIME Magazine and Statista's 2025 list of the World's Most Sustainable Companies. Beko's vision is 'Respecting the World, Respected Worldwide.' *Licensee limited to certain jurisdictions.**The data presented belongs to Arçelik A.Ş., a parent company of Beko. [i] 87/100 (as of 18 Feb 2025) Photo - - - View original content to download multimedia: SOURCE Beko Sign in to access your portfolio
Wall Street Journal
2 hours ago
- Wall Street Journal
Heard on the Street Friday Recap: European Negotiation
The S&P 500 closed at a record for the fifth session in a row. The S&P advanced 0.4% Friday and the Nasdaq Composite rose 0.2%, both hitting all-time highs. The Dow Jones Industrial Average added 208 points. Calmer Federal Reserve politics boosted the dollar. After a visit to the Fed's headquarters renovations, President Trump said he didn't think it was necessary to fire Chair Jerome Powell. The WSJ Dollar Index rose about 0.3%, while gold fell.
